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Type I interferon (IFN) dysregulation is a major contributory factor in the development of several 
autoimmune diseases, termed type I interferonopathies, and is thought to be the pathogenic link with 
chronic inflammation in these conditions. Anti‑neutrophil cytoplasmic antibody (ANCA)‑Associated 
Vasculitis (AAV) is an autoimmune disease characterised by necrotising inflammation of small blood 
vessels. The underlying biology of AAV is not well understood, however several studies have noted 
abnormalities in type I IFN responses. We hypothesised that type I IFN responses are systemically 
dysregulated in AAV, consistent with features of a type I interferonopathy. To investigate this, 
we measured the expression of seven interferon regulated genes (IRGs) (ISG15, SIGLEC1, STAT1, 
RSAD2, IFI27, IFI44L and IFIT1) in peripheral blood samples, as well as three type I IFN regulated 
proteins (CXCL10, MCP‑1 and CCL19) in serum samples from AAV patients, healthy controls and 
disease controls. We found no difference in type I IFN regulated gene or protein expression between 
AAV patients and healthy controls. Furthermore, IRG and IFN regulated protein expression did 
not correlate with clinical measurements of disease activity in AAV patients. Thus, we conclude 
that systemic type I IFN responses are not key drivers of AAV pathogenesis and AAV should not be 
considered a type I interferonopathy.
In recent decades, a role for altered type I interferon (IFN) responses in the development of autoimmunity has 
 emerged1,2. Type I IFNs are essential mediators of immune functions and are noted for their anti-viral, anti-
proliferative and immuno-regulatory  properties3. These cytokines regulate a wide range of biological processes 
and, under normal homeostatic conditions, their activation is tightly  regulated4. However, dysregulation of type 
I IFN responses can result in the development of inflammatory autoimmune  diseases5. First proposed as an inde-
pendent classification of autoimmune disease in 2011, such type I interferonopathies now include systemic lupus 
erythematosus (SLE), Aicardi Goutier syndrome, dermatomyositis and primary Sjogren’s syndrome (pSS)1,2,6,7.
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a group of systemic autoim-
mune disorders characterised by severe inflammation of the small blood vessels and surrounding  organs8. Three 
forms of AAV are recognised, each of which are associated with different clinical presentations: microscopic 
polyangiitis (MPA), granulomatosis with polyangiitis (GPA) and eosinophilic granulomatosis with polyangii-
tis (EGPA). Unusually for an autoimmune disease, AAV has a slightly higher incidence rate in males com-
pared to females and tends to develop later in life, with an average age of onset of 62 years  old9,10. The disease 
is usually characterised by the presence of autoantibodies (ANCA) directed against the neutrophil proteins 
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myeloperoxidase (MPO) or proteinase 3 (PR3)11–13 and binding of these autoantibodies results in neutrophil 
activation which induces a rapid onset pro-inflammatory  response14. Early diagnosis and treatment of these dis-
orders is crucial in preventing serious organ damage and death. However, due to a lack of knowledge regarding 
the underlying biology of the disease, no curative measures are currently available. Treatment options generally 
rely on broad immunosuppression using drugs such as corticosteroids which dampen the uncontrolled inflam-
mation. Although these treatments reduce the cell and tissue destruction created by immune dysregulation, the 
nonspecific nature of these treatments often result in adverse effects and poor outcomes for patients and so a 
need for more select and suitable alternatives is  clear15.
Interestingly, AAV shares both clinical and immunological similarities with known type I interferonopathies 
such as SLE and past studies have suggested a role for type I IFNs in AAV  severity16,17. In 2009, while studying 
the process of NETosis in AAV, Kessenbrock et al. found increased MxA expression, a typical interferon regu-
lated gene (IRG), in the glomeruli and tubules of active AAV patients. Additionally, they noted increased IFN-α 
concentrations in the serum of active AAV patients in comparison to AAV remission patients and healthy con-
trols, suggesting a role for these cytokines in AAV  activity16. In 2017, Ishizu et al. examined the gene expression 
profiles of Japanese MPA patients, noting a decrease in specific IFN regulated gene expression following remis-
sion induction treatment, and concluded that these genes are good markers of therapeutic  benefit17. However, 
to our knowledge, type I IFNs have never been conclusively investigated as causative factors of AAV initiation 
or progression and, with specific therapies designed to target various elements of type I IFN responses currently 
undergoing clinical trials for the treatment of type I interferonopathies, investigations into the role of these 
cytokines in AAV has become even more  pressing18,19.
We thus hypothesised that systemic type I IFN responses are dysregulated in AAV. In the present study we 
measured commonly used markers of type I interferonopathies in AAV patients and compared their expression 
to disease and healthy controls to determine whether type I IFN responses are dysregulated in AAV.
Results
Cohort characteristics. A total of 217 participants were recruited for this study comprising healthy con-
trols (n = 72), disease controls (n = 34), AAV active patients (n = 48), AAV remission patients (n = 35), SLE 
patients (n = 19) and pSS patients (n = 9). Four of these participants provided both active and remission matched 
samples, one DC (anti-GBM) and 3 AAV participants. This resulted in a total of 168 serum samples, 178 whole 
blood samples and 30 PBMC samples (Table 1).
Active AAV disease is clinically defined by a Birmingham vasculitis activity score (BVAS) of ≥ 1. However, in 
order to exclude cases of persistent mild inflammation from our study our active cohort were selected to have 
a BVAS ≥ 3. AAV patients in remission were defined by a BVAS of zero. A summary of clinical measurements 
used to define and study our AAV participants is shown in Table 2.
To evaluate potential effects of general kidney inflammation and systemic autoimmunity on type I IFN 
responses, a disease control group comprised of patients diagnosed with a spectrum of kidney diseases and/
or autoimmune disorders were included in this study. These included diagnoses of anti-glomerular basement 
membrane (anti-GBM) disease (n = 12), chronic kidney disease (CKD; n = 7), classical polyarteritis nodosa (PAN) 
(n = 1), chronic pyelonephritis (n = 1), diabetic kidney disease (n = 4), IgA vasculitis (n = 4), rheumatoid vasculitis 
(n = 1) and rheumatoid arthritis (n = 4). Samples collected from known type I interferonopathies (SLE; n = 19 
and pSS; n = 9) were also utilised as positive disease controls in this study. Further information regarding disease 
activity and treatment of disease controls is shown in Supplementary Tables 1 and 2.
Peripheral IRG expression is not upregulated in AAV. Expression of specific IRGs are elevated in 
blood from patients with type I interferonopathies and correlate with disease severity in these  conditions2,20,21; 
therefore, we investigated the expression of a panel of these IRGs (ISG15, SIGLEC1, STAT1, RSAD2, IFI27, 
IFI44L and IFIT1) using mRNA extracted from whole blood samples. These genes are upregulated in the pres-
ence of type I IFNs and are often adopted as surrogate markers of type I IFN activity which can otherwise be 
difficult to  detect4,5,18,22,23. They are continuously found to be dysregulated in transcriptomic analysis of known 
type I interferonopathies and are therefore commonly used to investigate the transcriptional activity of type I 
IFNs in such disease settings (Supplementary Table 3)2,6,18,20.
Table 1.  Cohort summary: All participants have been categorised as either Healthy controls (HC), Disease 
controls (DC), AAV patients (Active {A} or Remission{R}), Systemic Lupus Erythematosus (SLE) or primary 
Sjogren’s syndrome (pSS). A summary of the samples obtained as well as the median age and sex breakdown is 
shown. Age and sex breakdown for the HC cohort is based off of whole blood and serum donors only (n = 67) 
as this data was unavailable for participants involved in PBMC analysis (n = 5).
Cohort summary HC DC AAV R AAV A SLE pSS
N
Participants 72 34 35 48 19 9
Serum samples (n) 67 31 29 41 0 0
Whole Blood Samples (n) 62 29 27 41 19 0
PBMC samples (n) 5 4 6 6 0 9
Age, median (range), years 51 (16–83) 60 (16–87) 62 (25–80) 65 (22–84) 44 (28–60) 57 (52–73)
Male, n (%) 24 (36) 20 (57) 20 (17) 24 (50) 2 (11) 1 (11)
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No significant difference in whole blood IRG expression was noted between AAV samples (active or remis-
sion), disease controls or healthy control groups, whereas samples collected from a known type I Interferonopa-
thy, SLE, showed notably increased expression across all genes measured with the exception of STAT1 (Fig. 1a). 
Expression in all samples were independent of sex while AAV data exhibited only weak to moderate correlations 
with age (Supplementary Figs. 1a and 2a; Supplementary Table 4).
We observed significantly higher expression of the genes MMP8 and AXA3 in our active AAV group com-
pared to HCs (p < 0.05; Fig. 1b), neither of which are primarily type I IFN  regulated24,25, indicating that our 
experimental system can detect such signals. This is consistent with existing  literature26, confirming that our 
AAV cohort exhibits expected gene expression characteristics, but that systemic IRG expression is not specifi-
cally altered in this condition.
We also calculated an IFN score for each sample in our cohort. While SLE samples showed a significantly 
increased IFN score compared to all other cohorts, no differences in the median IFN score was noted between 
AAV samples, disease controls and healthy controls (Fig. 1c). Of the 24 positive IFN score samples detected, 3 
were (4.8%) healthy control, 2 (6.7%) disease control, 3 (11.1%) AAV remission patient samples, 3 (7.3%) AAV 
active patient samples and 13 SLE patient samples (68.4%) (Fig. 1c). The percentage of healthy control and 
interferonopathy groups with a positive IFN score in our study is consistent with those of previous  studies2,18.
Changes to whole blood cell composition is common in disease pathology, including in AAV, where patients 
often exhibit altered leukocyte cell  counts27,28. Different cell subsets have different gene expression  profiles29 so 
varying blood cell composition can affect transcriptional  analysis30,31. To assess any potential effects that differ-
ential cell counts may have on our analysis, the absolute cell counts available for each participant were correlated 
with their corresponding IFN scores. Only weak to moderate correlations, none of which were significant, were 
found between IFN scores and total white blood cell counts, which included cell counts for neutrophils, lym-
phocytes, eosinophils and platelets (Supplementary Fig. 5).
Finally, we examined this IRG signature (ISG15, SIGLEC1, STAT1 RSAD2, IFI27 and IFI44L) in peripheral 
blood mononuclear cells (PBMCs) collected from a smaller cohort of healthy controls, disease controls, AAV 
and primary Sjogren’s syndrome (pSS) patients. Numerous studies have reported an upregulation of IRGs in the 
peripheral blood and salivary glands of pSS patients, resulting in its classification as a type I interferonopathy 
(Supplementary Table 3)7,32. We observed upregulation of IRGs in PBMCs collected from pSS patients compared 
to all other cohorts, yet we again found no significant differences in IRG expression between AAV (active or 
remission) PBMC samples and both disease and healthy control groups (Supplementary Fig. 3). We calculated 
IFN scores for all samples, which confirmed that pSS samples had significantly increased IFN scores compared 
to all other cohorts while no significant differences in the median IFN score was noted between AAV samples, 
disease controls and healthy controls (Fig. 1c). Of the 9 positive IFN score samples detected, 1 was a disease 
control sample (25%), 1 was an AAV active patient samples (16.7%) and 7 were pSS patient samples (77.8%) 
(Fig. 1c). Together, our results confirm that there is no elevation in the IFN transcriptional signature in either 
PBMC or whole blood samples from AAV patients.
Table 2.  AAV Characteristics: AAV participants have been divided into AAV R and AAV A cohorts with a 
further delineation of AAV A into treated (Txt) and treatment naïve (Txt Naïve) participants. A summary 
of clinical characteristics including ANCA status, diagnosis, Birmingham Vasculitis Activity Score (BVAS), 
C-reactive protein (CRP) cytokine levels, creatinine, estimated Glomerular Filtration Rate (eGFR) and 
treatment history is shown. IQR; interquartile range.
AAV characteristics AAV R
AAV A
Txt Txt Naive
N Patients 35 37 11
ANCA status, n (%)
Anti-MPO 19 (54) 16 (43) 9 (82)
Anti-PR3 16 (46) 21 (57) 2 (18)
Diagnosis, n (%)
GPA 16 (46) 20 (54) 1 (9)
MPA 19 (54) 17 (46) 10 (91)
BVAS, median (range) 0 14 (3–32) 14 (12–27)
CRP (mg/dL), median (IQR) 3 (10.8–9.8) 18.5 (5.3–77.8) 46 (39–112)
Creatinine (μmol/L), median (IQR) 119.5 (86.5–166.5) 136.5 (89.5–296.5) 247 (201–416)
eGFR(ml/min), median (IQR) 49.5 (32.3–34.8) 42 (15–73) 17.5 (11–23)
Immunosuppression treatment, n (%)
Cyclophosphamide 0–6 months 5 (13.9) 3 (8.1) N/A
Azathioprine Current 14 (38.9) 4 (10.8) N/A
MMF Current 9 (25) 5 (13.5) N/A
Methotrexate Current 2 (5.6) 0 N/A
Rituximab 0–6 months 2 (5.6) 2 (5.4) N/A
Corticosteroid Current 24 (66.7) 30 (81.1) N/A
Other Current 7 (19.4) 5 (13.5) N/A
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Type I IFN regulated protein expression does not differ between AAV and healthy con‑
trols. We next measured the serum concentration of three type I IFN regulated chemokines: MCP-1, CCL19 
and CXCL10. Although these chemokines can be regulated by several inflammatory mediators, they have previ-
ously been validated as robust biomarkers of type I interferonopathies (Supplementary Table 3)1,33. We found no 
significant differences in the serum concentration of MCP-1, CCL19 or CXCL10 in AAV patients compared to 
HC and DC (Fig. 2). Levels of these chemokines in all cohorts were independent of sex and showed only weak to 
moderate correlations with age (Supplementary Figs. 1b and 2b; Supplementary Table 4).
Immunosuppression treatment does not affect IRG expression, but AAV treatment naïve 
patients have significantly increased CXCL10 serum concentrations. The immunosuppressive 
treatments received by AAV patients in this cohort are known to alter the expression of inflammatory media-
tors. Therefore, we investigated whether treatment naïve patients had elevated expression and potential effects of 
these drugs on type I IFN responses in AAV. Immunosuppressive treatment did not affect IRG expression, with 
treatment naïve (TxN) samples and treated (Tx) samples showing similar levels for all IRGs measured (Fig. 3a).
We also observed no differences in MCP-1 or CCL19 concentrations between treated and treatment naïve 
samples (Fig. 3b). However, we did observe a significant increase in CXCL10 in treatment naïve samples (Fig. 3b; 
p < 0.05), which was not seen in treatment naïve disease control patients.
IRG and type I IFN regulated protein expression does not correlate with AAV severity. To 
explore potential relationships between type I IFN responses and AAV severity, we examined the correlation of 
type I IFN regulated protein and gene expression with three clinical measurements of AAV severity: BVAS, CRP 
concentrations and creatinine levels. We found no significant (p < 0.05) or strong (r > 0.5) correlations between 
type I IFN regulated gene or protein expression data and any of these clinical measurements (Table 3).
Discussion
The purpose of this study was to investigate whether systemic type I IFN responses are dysregulated in AAV, 
indicative of a type I interferonopathy. Both transcriptional and translational mediators of type I IFN responses 
were measured following previously described methods commonly used in the identification and study of exist-
ing type I  interferonopathies20,33. Overall, our results indicate no link between systemic type I IFN regulated 
gene and protein expression and AAV, suggesting that AAV is not a type I interferonopathy and that patients are 
therefore unlikely to benefit from interferon inhibiting therapies.
Diseases such as SLE, Aicardi Goutier syndrome, dermatomyositis and Sjogren’s syndrome are examples of 
autoimmune conditions that have been classified as type I interferonopathies due to alterations in systemic type 
I IFN  responses1,2,6,7. Dysregulation of type I IFN responses are implicated as drivers of the meta-inflammation 
characteristic of these conditions and elevated type I interferon regulated gene and protein expression often act 
as hallmarks for these type I  interferonopathies2,20,33,34. As well as showing abnormal IFN regulated expression, 
IFN activity in type I interferonopathies often directly correlates with clinical severity measurements and out-
comes of these patients. In SLE, for example, IFN responses have been shown to directly correlate with the SLE 
disease activity index (SLEDAI)33,35. Despite the lack of significant differences in type I IFN regulated gene and 
protein expression between AAV samples and control samples we explored the idea that type I IFN responses 
may still have a role in AAV disease severity, postulating that high IFN regulated expression may correlate with 
the presence of severe acute disease. We found no strong correlations between standard clinical measurements of 
AAV (including BVAS, creatinine levels and CRP concentrations) and type I IFN regulated expression at either 
a transcriptional or a translational level. We also did not find any evidence that the cellular composition of our 
samples influenced the IFN scores that we generated in our AAV cohort, however we do note that we did not 
perform cell type specific analysis and this is a limitation of our findings. Together, our analysis suggests that 
type I IFNs and associated responses are not key drivers of AAV disease pathogenesis.
Treatment for AAV consists of broad immunosuppression and it is possible that immunosuppressive drugs 
impact on systemic type I IFN responses. We found that treatment naïve AAV patients have significantly higher 
concentrations of circulating CXCL10 when compared to treated patients suggesting that the immunosuppressive 
Figure 1.  IRG expression in AAV patients and controls. Whole blood samples were obtained from healthy 
controls (HC; n = 62), disease controls (DC; n = 29), AAV remission patients (AAV R; n = 27), AAV active 
patients (AAV A; n = 41) and SLE patients (n = 19). PBMC samples were obtained from healthy controls (HC; 
n = 5), disease control (DC; n = 4), AAV remission (AAV R; n = 6), AAV Active (AAV A; n = 6) and primary 
Sjogren’s syndrome (pSS; n = 9). qPCR was used to quantify gene expression and all data is shown relative to 
the expression of the endogenous control gene RPL27 and normalised to the median expression of the healthy 
control samples  (2−ΔΔCT). (a) Gene expression measurements of the IRGs (i) ISG15, (ii) SIGLEC1, (iii) STAT1 
(iv) RSAD2 (v) IFI27, and (vi) IFI44L in whole blood from HC, DC, AAV R, AAV A and SLE groups, (vii) IFIT1 
in HC, DC, AAV R and AAV A groups only. Due to technical issues IFIT1 expression analysis could not be 
performed on SLE samples. (b) Gene expression measurements of (i) MMP8 and (ii) ANXA3 in whole blood 
HC, AAV R and AAV A groups. (c) (i) IFN scores calculated and plotted for each whole blood sample analysed. 
(ii) Percentage of positive (red) and negative (white) IFN scores in each cohort studied from whole blood 
samples. (iii.) IFN scores calculated and plotted for each PBMC sample analysed. (iv.) Percentage of positive 
(red) and negative (white) IFN scores in each cohort studied from PBMC samples. Whole horizontal lines 
represent the median and IQR of each cohort. Statistical analysis was performed using One-Way ANOVA with 
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drugs received by these individuals act to suppress CXCL10 production. Interestingly, investigations into the 
role of type I IFNs in autoimmune Addison’s disease (AAD) show a similar CXCL10 finding between patients 
and healthy  controls36,37. Although AAD has not officially been categorised as a type I interferonopathy, one 
study has found dysregulation in the negative regulators of type I IFN responses in T cells of patients with AAD 
following  stimulation36. This data suggests that, at baseline, type I IFN regulated gene expression is standard 
in AAD but T cells isolated from these patients fail to respond appropriately to immune stimulation resulting 
in alterations to type I IFN regulated responses. This raises the intriguing question of whether basal type I IFN 
responses also remain intact in AAV but an inability to appropriately respond to immune challenges occurs, or 
furthermore whether dysregulation of IFN signalling is specific to certain cell types which may become diluted 
in whole blood analysis. It is important to note, however, that although CXCL10 has been proven to be a useful 
biomarker of type I interferonopathies in the  past1, it is also known to be upregulated in several other autoim-
mune disorders, so this upregulation is not necessarily specific to type I  interferonopathies38. CXCL10 expression 
can be upregulated by several immune factors in addition to type I IFNs, in particular IFNγ, a type II IFN. IFNγ 
production is reported to be upregulated in AAV and genes involved in IFNγ signalling pathways have been 
proposed to have novel roles in AAV pathogenesis suggesting that perhaps the upregulation of CXCL10 seen 
here in treatment naive AAV active patients is a result of type II IFN  activity39,40.
Each of the proteins analysed here have been investigated in AAV previously and although our results agree 
with some of these studies, they contradict the findings of others. For example, similar to our observations, 
Monach et al. showed a significant increase of CXCL10 in AAV serum samples compared to healthy controls, 
however unlike our study, this find was independent of disease status while also showing no significant effects of 
 treatment41. These conflicting results warrant further investigation however may be partially explained through 
differences in study design. For instance, samples used by Monach et al. were received through the RAVE trial, 
a trial testing the efficacy of rituximab in the treatment of  AAV41,42. These patients were therefore undergoing a 
strict treatment regimen with little to no crossover with other medications. In contrast, participants in our treated 
cohort were often on various treatment options simultaneously and this has likely affected our results. Variable 
prednisone treatment before rituximab therapy can affect IFN scores in rheumatoid arthritis patients and so 
differences in treatment regimens between the studies is clearly an important variable to  note43. Although our 
findings are therefore limited in that they cannot be attributed to the effects of one specific treatment, this is pos-
sibly a more realistic overview of treated AAV cohorts with combination therapies being routinely  prescribed44. 
Additionally, differences in CXCL10 concentrations observed between the two studies may be a consequence 
of the differential assay sensitivities noted between our two methods of protein detection, with Monach et al. 
observing discrete but significant differences between their  cohorts41. Indeed, the median values of circulating 
CXCL10 were higher in both our remission (103.6 pg/ml) and active (130 pg/ml) AAV patient samples when 
compared to that of healthy controls (93.47 pg/ml), however this did not reach statistical significance. It is worth 
noting that the median CXCL10 levels detected in our cohort (AAV, DC and HC) correspond with the serum 
concentration range of CXCL10 reported in the healthy control cohorts of various studies that use ELISAs as a 
means of protein  detection45–47. However, it is clear that the role of CXCL10 in AAV pathogenesis remains to be 
fully elucidated. Again, our MCP-1 and CCL19 results both agree  with48,49 and contradict previous  studies50,51. 
However studies that contradict our findings had sample sizes significantly smaller than those used  here50,51. 
Our large sample size is a strength of this work acting to minimise the likelihood of a type II error in our analysis 
(Supplementary Table 6).
This study is not without limitations and these are important to note. The main focus of this work was to 
investigate systemic type I IFN responses to determine whether AAV could be classified as a type I interferonopa-
thy, as is standard practice in the study and diagnosis of type I  interferonopathies1,20. As such, tissue and organ 
specific analysis was not investigated so a role for type I IFNs at local sites of inflammation cannot be ruled out. 
Several autoimmune diseases have site-specific upregulation of type I IFNs  responses52. Indeed, increased gene 
expression of MX1, an IRG, was observed in the glomeruli of AAV patients with active disease by Kessenbrock 
et al. suggesting a localised change in IFN responses in active AAV  patients16.
Another limitation is that only four matched active and remission samples were available for this study, three 
AAV participants and one in the disease control group, thus making robust analysis of matched samples difficult. 
Although increasing numbers of matched samples would have strengthened investigation of type I IFN responses 
Figure 2.  Serum concentrations of Type 1 IFN regulated chemokines expression In AAV patients and controls. 
Serum samples were obtained from HC (n = 67), DC (n = 31), AAV R patients (n = 29) and AAV A patients 
(n = 41). The concentration of circulating (a) MCP-1, (b) CCL19 and (c) CXCL10 were measured using ELISAs. 
Whole horizontal lines represent the median and IQR of each cohort. Statistical analysis was performed using 
One-Way ANOVA with Dunn’s multiple comparison testing. No statistical differences were observed.
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Figure 3.  The effects of immunosuppressive treatment on type I IFN regulated gene expression and protein 
expression. Whole blood samples were obtained from treated AAV remission patients (n = 27), treated AAV 
active patients (Tx; n = 31) and treatment naïve AAV active patients (TxN; n = 10). qPCR was used to quantify 
the expression of seven IRGs (a); IRGs (i) ISG15, (ii) IFIT1, (iii) SIGLEC1, (iv) RSAD2 (v) IFI27, (vi) IFI44L and 
(vii) STAT1. Gene expression data is shown relative to the expression of the endogenous control gene RPL27 
and normalised to the median expression of the healthy control samples  (2−ΔΔCT). Matching serum samples were 
collected from AAV remission (n = 29), treated AAV active patients (Tx; n = 31) and treatment naïve AAV active 
patients (TxN; n = 10). (b) Serum concentrations of circulating (i) MCP-1, (ii) CCL19 and (iii) CXCL10 were 
measured using ELISAs. Whole horizontal lines represent the median and IQR of each cohort and statistical 
analysis was performed using One-Way ANOVA with Dunn’s multiple comparison testing.
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in AAV disease progression and relapse, the stratification of our AAV cohort into active and remission groups, 
which even post-stratification had sufficient numbers for well-powered analysis, and the availability of matched 
clinical measurements provides significant insight into relationships between systemic type I IFN responses 
and disease activity.
The heterogenous nature of our AAV disease control cohort acts as an additional limitation to this study. 
Samples from a variety of diseases were purposefully chosen to analyse potential contribution of general kidney 
inflammation and systemic autoimmune disorders to enable the identification of AAV specific upregulation. 
However, for each group, small numbers, range of disease severities and treatments made singular disease com-
parison difficult and possibly blunted any signals that may have otherwise been observed in specific disease 
 settings53.
Overall, this study was carried out with the aim of better understanding the underlying immune processes 
behind AAV progression with the potential to provide a more specific target for future treatment of AAV. Our 
work indicates that systemic type I IFN responses are not key drivers in AAV pathogenesis and so patients are 
unlikely to benefit from treatments that target these  cytokines18,19. We have shown that systemic type I IFN 
responses are not dysregulated in AAV and that these responses do not correlate with AAV disease severity.
Methods
Participant recruitment. All AAV, HC and DC participant samples used in this study were provided by 
the Rare Kidney Disease (RKD) Registry and Biobank of Ireland (www. tcd. ie/ medic ine/ thkc/ resea rch/ rare. php) 
which has full ethical approval for the sampling and processing of human biological samples from the ethical 
committees of each participating hospital (St. Vincent’s Hospital Research ethics committee, Tallaght Hospital 
Research ethics committee, St. James’ Hospital Research ethics committee, and Beaumont Hospital Research 
ethics committee). These samples were collected and stored in accordance with the RKD sample and data collec-
tion and management protocol from participating centres across the country. SLE patient samples were obtained 
in from the Leeds Institute of Rheumatic and Musculoskeletal Medicine at the University of Leeds and the NIHR 
Leeds Biomedical Research Centre. Ethical approval for the use of these samples in such research has been 
provided by the South Yorkshire research ethics committee. All patients with primary Sjogren’s syndrome (pSS) 
included in our study met the American-European Consensus classification  criteria54 and were recruited from 
Royal Victory eye and Ear Hospital, Dublin. The study protocol was conducted in accordance with the Helsinki 
Declaration and approved by the institutional review boards of the Royal Victory eye and Ear Hospital. Every 
participant involved in this study has provided written informed consent.
Gene expression analysis. Whole blood samples (HC, DC and AAV) that were previously collected and 
stored at − 80 °C in Qiagen PaxGene blood tubes were thawed to room temperature. RNA was extracted follow-
ing the PaxGene RNA extraction kit protocol (Qiagen). These samples were bioanalysed using the Agilent RNA 
6000 Nano kit on an Agilent 2100 Bioanalyzer following the procedures described in the kit guide. Samples with 
RNA integrity numbers (RIN) greater than 6 and yields higher than 30 ng/μl were selected for use.
Whole blood samples (SLE) that were collected in Tempus blood RNA tubes were extracted following the 
protocols outlined in the Preserved Blood RNA Purification Kit I (for use with Tempus Blood RNA tubes) 
(Norgen Biotek). These RNA samples were then subjected to DNAse treatment using the RNase-Free DNase I 
Kit (Norgen Biotek) in accordance with the manufacturer’s instructions.
PBMCs were isolated from whole blood using density centrifugation techniques. RNA from AAV, HC and 
DC PBMC samples were extracted using the PureLink RNA extraction kit (Thermo Fisher Scientific) while RNA 
from pSS PBMC samples were extracted using TRI reagent (Sigma) according to manufacturer’s instructions. All 
RNA samples extracted from PBMCs were DNAse treated using the Invitrogen DNAse I, Amplification Grade 
kit following the protocols provided with this kit.
Table 3.  Correlation of type I IFN responses with clinical measurements of AAV: Whole blood IRG gene 
expression data, as well as type I IFN regulated protein concentration data, collected from AAV patients (both 
active and remission) were correlated with matched BVAS, CRP and Creatinine levels. Spearman correlation 
analysis was used to generate correlation coefficient values, indicated in the table, and to determine the 
significance of these relationships. No statistically significant correlations were observed.
BVAS CRP Creatinine
Gene expression
ISG15  − 0.18 0.04  − 0.21
SIGLEC1  − 0.05  − 0.08  − 0.19
IFIT1  − 0.03  − 0.06  − 0.03
RSAD2  − 0.10 0.07  − 0.17
IFI27  − 0.13 0.08  − 0.10
IFI44L  − 0.21  − 0.12  − 0.02
STAT1  − 0.12 0.08  − 0.23
Protein expression
CXCL10 0.15 0.19 0.02
MCP-1 0.05  − 0.08 0.18
CCL19 0.18 0.20 0.13
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Extracted RNA was immediately placed on ice, nanodropped and stored at – 80 °C. For all RNA samples 
extracted from whole blood 250 ng of high-quality RNA was reverse transcribed into cDNA, while for RNA 
samples extracted from PBMCs 500 ng of RNA was reverse transcribed into cDNA both following the protocols 
accompanying the ThermoFisher High-Capacity cDNA Reverse Transcription Kit. The cDNA produced was 
stored at − 20 °C until used.
All Primers were designed using the NCBI BLAST database to amplify a product of maximum 200 bps and 
were designed to be intron spanning where possible (See Supplementary Table 7). qPCR was carried out using 
Sybr green and ran on a QuantStudio 5 qPCR machine.
IFN score calculation. An IFN score for each sample was calculated following previously described 
 methods2,18. This was calculated as the median fold change of the seven IRGs for each sample when compared to 
the median of the healthy control samples. Abnormal IFN scores were defined as those higher than 2 standard 
deviations from the mean IFN score of healthy control samples i.e. those higher than 4.227 for whole blood gene 
expression analysis and 7.3 for PBMC gene expression analysis. Samples with an IFN score greater than this were 
labelled as IFN positive while any score below this measure were labelled as IFN negative.
Enzyme linked immunosorbent assays (ELISAs). ELISA was used to quantify serum concentrations 
of CXCL10, MCP-1 and CCL19. These were carried out following the protocols specified by each ELISA kit (BD 
Biosciences for CXCL10 and MCP-1; R&D Systems for CCL19).
Data analysis and statistics. All statistical analyses were performed using GraphPad Prism v8.4.2 with 
the exception of the power calculations which were determined using R software. Shapiro–Wilk tests were used 
to determine normality. All data was found to be non-normally distributed. Therefore, statistical significance 
between each sample cohort was determined using Kruskal–Wallis one-way ANOVA, with Dunn’s post hoc 
multiple comparison tests, while Spearman’s Correlation tests were used to analyse associations between clinical 
measurements or demographic data and experimental data. The strength of these correlations were defined fol-
lowing published guidelines with Spearman correlation coefficients greater than 0.5 deemed strong, those below 
0.3 deemed weak associations while those between 0.3 and 0.5 are acknowledged as moderate  associations55,56. 
We confirmed the power of our analysis using a one-way balanced ANOVA power calculation as a baseline com-
parison. The mean number of samples per group in our experiments were used as the estimate for the per group 
sample size, and the conservative assumption that the standardised means of the three disease groups differed 
from the control group by delta = 0.25, 0.5, and 0.75 in some combination was made. Under these settings, our 
calculated biological power of the analyses ranged from 84 to 87% (Supplementary Table 6).
Data availability
All data will be made available in Excel format through the online open access repository Zenodo. https:// doi. 
org/ 10. 5281/ zenodo. 39498 00.
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